Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
01 2022
Historique:
received: 02 01 2021
revised: 07 07 2021
accepted: 30 08 2021
pubmed: 5 9 2021
medline: 31 3 2022
entrez: 4 9 2021
Statut: ppublish

Résumé

Developing strategies to inflame tumors is critical for increasing response to immunotherapy. Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell infiltration and enables responsiveness to combinatorial immunotherapy in an IFN-dependent manner. Treatment efficacy relied upon mobilizing both adaptive and innate immunity and depended on both cytotoxic CD4

Identifiants

pubmed: 34479871
pii: 2159-8290.CD-21-0003
doi: 10.1158/2159-8290.CD-21-0003
pmc: PMC9401506
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108-133

Informations de copyright

©2021 The Authors; Published by the American Association for Cancer Research.

Références

J Virol. 2012 Jun;86(12):6792-803
pubmed: 22491469
Cell. 2020 Jun 25;181(7):1612-1625.e13
pubmed: 32497499
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Nature. 2019 Jul;571(7764):270-274
pubmed: 31207604
Lab Anim. 2018 Aug;52(4):341-350
pubmed: 29310487
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
J Immunother Cancer. 2019 Aug 26;7(1):223
pubmed: 31446896
J Immunol. 2011 Mar 1;186(5):3047-57
pubmed: 21307297
Cytometry A. 2011 Feb;79(2):167-74
pubmed: 21265010
Front Immunol. 2019 Nov 15;10:2689
pubmed: 31803194
Cancer Res. 2007 May 1;67(9):4507-13
pubmed: 17483367
Cancer Res. 2012 Jul 15;72(14):3439-44
pubmed: 22761338
Nat Rev Immunol. 2020 Feb;20(2):128-136
pubmed: 31591533
Science. 2011 Mar 25;331(6024):1612-6
pubmed: 21436454
Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):701-711
pubmed: 33045316
Front Immunol. 2018 Apr 23;9:827
pubmed: 29740438
Carcinogenesis. 2000 Apr;21(4):585-91
pubmed: 10753190
J Clin Oncol. 2020 Feb 10;38(5):395-405
pubmed: 31774688
Immunity. 2009 Nov 20;31(5):823-33
pubmed: 19913446
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33106386
Nature. 2002 Oct 17;419(6908):734-8
pubmed: 12384702
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Immunity. 2014 Nov 20;41(5):843-52
pubmed: 25517616
J Immunol. 2011 Oct 1;187(7):3555-64
pubmed: 21880986
Int J Cancer. 2016 Nov 15;139(10):2157-68
pubmed: 27299986
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):728-34
pubmed: 15701862
Nature. 2019 Jul;571(7764):265-269
pubmed: 31207605
Lancet Oncol. 2019 Aug;20(8):e417-e433
pubmed: 31364594
Methods Mol Biol. 2020;2148:331-345
pubmed: 32394392
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
Nat Immunol. 2002 Dec;3(12):1142-9
pubmed: 12426565
Cancer Cell. 2013 Mar 18;23(3):277-86
pubmed: 23518347
Blood. 2005 Apr 1;105(7):2862-8
pubmed: 15591121
Immunity. 2019 Jan 15;50(1):181-194.e6
pubmed: 30635236
Nat Med. 2018 Dec;24(12):1845-1851
pubmed: 30397353
J Clin Oncol. 2019 Sep 20;37(27):2460-2471
pubmed: 31403857
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Immunol. 2005 Sep 1;175(5):2825-33
pubmed: 16116168
Int J Radiat Oncol Biol Phys. 1992;22(5):847-51
pubmed: 1555975
F1000Res. 2020 Jan 27;9:47
pubmed: 32789006
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Nat Med. 2019 Jan;25(1):89-94
pubmed: 30510250
Immunity. 2016 Aug 16;45(2):415-27
pubmed: 27533016
Cancer Res. 2011 Apr 1;71(7):2488-96
pubmed: 21300764
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
Science. 2008 Nov 14;322(5904):1097-100
pubmed: 19008445
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Cancer Immunol Res. 2013 Oct;1(4):235-44
pubmed: 24396833
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
J Exp Med. 2010 Mar 15;207(3):651-67
pubmed: 20156973
Cancer Cell. 2019 Jun 10;35(6):885-900.e10
pubmed: 31185212
Immunity. 2020 Jan 14;52(1):151-166.e6
pubmed: 31924474
J Immunol. 2002 Oct 15;169(8):4098-102
pubmed: 12370336
Elife. 2018 Feb 28;7:
pubmed: 29488879
Cell. 2019 Apr 18;177(3):556-571.e16
pubmed: 30955881
Cancer Cell. 2013 Nov 11;24(5):589-602
pubmed: 24209604
J Exp Med. 2010 Jun 7;207(6):1283-92
pubmed: 20479118
Clin Cancer Res. 2013 Mar 1;19(5):1035-43
pubmed: 23460534
PLoS One. 2013 Dec 23;8(12):e83384
pubmed: 24376696
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1099-107
pubmed: 25442041
BMC Genomics. 2020 Jan 2;21(1):2
pubmed: 31898484
N Engl J Med. 2012 Mar 8;366(10):925-31
pubmed: 22397654
J Exp Med. 2021 Feb 1;218(2):
pubmed: 33156338
Nature. 2019 Aug;572(7768):254-259
pubmed: 31316209
Cancer Immunol Res. 2019 Mar;7(3):428-442
pubmed: 30642833
J Biomed Sci. 2015 Oct 20;22:91
pubmed: 26486970
Ann Oncol. 2017 Aug 01;28(8):2002-2008
pubmed: 28520840
Nat Immunol. 2015 Jul;16(7):708-17
pubmed: 26054719
Annu Rev Med. 2020 Jan 27;71:47-58
pubmed: 31412220
Front Immunol. 2019 May 24;10:1176
pubmed: 31178872
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Cell. 2020 Apr 16;181(2):442-459.e29
pubmed: 32302573
Nat Rev Cancer. 2020 Apr;20(4):218-232
pubmed: 32024970
Front Immunol. 2017 Sep 20;8:1160
pubmed: 28979263
Gynecol Oncol. 2011 Feb;120(2):224-8
pubmed: 21075438
Nature. 2019 Jul;571(7764):211-218
pubmed: 31207603
Nature. 2015 Apr 16;520(7547):373-7
pubmed: 25754329
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
Immunity. 2020 May 19;52(5):825-841.e8
pubmed: 32396847
J Exp Med. 2010 Mar 15;207(3):637-50
pubmed: 20156971
Nat Commun. 2021 May 20;12(1):2965
pubmed: 34017005
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
J Immunol. 2005 Apr 15;174(8):4480-4
pubmed: 15814668
J Immunol. 2005 Aug 1;175(3):1483-90
pubmed: 16034085
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9452-7
pubmed: 12878725
Nature. 2020 Apr;580(7802):257-262
pubmed: 32269339
J Clin Invest. 2012 Oct;122(10):3718-30
pubmed: 22945631
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
Nat Immunol. 2006 Jul;7(7):755-62
pubmed: 16732291
CA Cancer J Clin. 2017 Jan;67(1):65-85
pubmed: 27570942
Nature. 2018 Oct;562(7727):367-372
pubmed: 30283141
Cancer Discov. 2016 Jan;6(1):71-9
pubmed: 26493961
Front Immunol. 2017 Mar 24;8:325
pubmed: 28392788
Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22699-22709
pubmed: 31636208
J Exp Med. 2012 Oct 22;209(11):2113-26
pubmed: 23008334
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92
pubmed: 18818309
Clin Cancer Res. 2017 Nov 15;23(22):6771-6780
pubmed: 28855352
J Immunol. 2008 Sep 1;181(5):3099-107
pubmed: 18713980
Clin Cancer Res. 2020 Mar 1;26(5):1025-1033
pubmed: 31796520
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
Nat Med. 2020 Feb;26(2):193-199
pubmed: 32042196
Nat Med. 2016 Dec;22(12):1402-1410
pubmed: 27775706
J Immunol. 2005 Jun 15;174(12):7516-23
pubmed: 15944250
Immunity. 2014 Feb 20;40(2):289-302
pubmed: 24530057

Auteurs

Fernanda G Herrera (FG)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.
Radiation Oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

Catherine Ronet (C)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.

Maria Ochoa de Olza (M)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.
Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

David Barras (D)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.

Isaac Crespo (I)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.

Massimo Andreatta (M)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.

Jesus Corria-Osorio (J)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.

Aodrenn Spill (A)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.

Fabrizio Benedetti (F)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.

Raphael Genolet (R)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.

Angela Orcurto (A)

Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

Martina Imbimbo (M)

Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

Eleonora Ghisoni (E)

Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

Blanca Navarro Rodrigo (B)

Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

Dominik R Berthold (DR)

Medical Oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

Apostolos Sarivalasis (A)

Medical Oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

Khalil Zaman (K)

Medical Oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

Rafael Duran (R)

Department of Radiology and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland.

Clarisse Dromain (C)

Department of Radiology and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland.

John Prior (J)

Department of Nuclear Medicine, Lausanne University Hospital, Lausanne, Switzerland.

Niklaus Schaefer (N)

Department of Nuclear Medicine, Lausanne University Hospital, Lausanne, Switzerland.

Jean Bourhis (J)

Radiation Oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

Georgia Dimopoulou (G)

Unit of Translational Oncopathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.

Zoi Tsourti (Z)

Unit of Translational Oncopathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.

Marius Messemaker (M)

Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts.

Thomas Smith (T)

NanoString Technologies Inc., Seattle, Washington.

Sarah E Warren (SE)

NanoString Technologies Inc., Seattle, Washington.

Periklis Foukas (P)

Second Department of Pathology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Sylvie Rusakiewicz (S)

School of Nursing, National and Kapodistrian University of Athens, Athens, Greece.

Mikaël J Pittet (MJ)

Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts.
Department of Pathology and Immunology, and Department of Oncology, University of Geneva, Geneva, Switzerland.

Stefan Zimmermann (S)

Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

Christine Sempoux (C)

Unit of Translational Oncopathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.

Urania Dafni (U)

School of Nursing, National and Kapodistrian University of Athens, Athens, Greece.

Alexandre Harari (A)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.

Lana E Kandalaft (LE)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.
Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

Santiago J Carmona (SJ)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.

Denarda Dangaj Laniti (D)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.

Melita Irving (M)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.

George Coukos (G)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland. George.Coukos@chuv.ch.
Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH